Lotus Pharmaceutical Co. Ltd. announced that the U.S. Food and Drug Administration (USFDA) has granted the final approval for the Company's Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, 5 mg, 10 mg, 15 mg and 25 mg, generic version of BMS/Celgene Corporation's Revlimid. Lotus' Lenalidomide Capsules, 2.5 mg and 20 mg remain tentatively approved because of the exclusivity granted to the first ANDA filer for these strengths.

Lotus/Alvogen expects to launch the product as per its settlement agreement with the originator in the US.